| CORNELISSEN, Jan J., Alois GRATWOHL, Richard F. SCHLENK, Gorge SIERRA, Martin BORNHÄUSER, Gunnar JULIUSSON, Zdeněk RÁČIL, Jacob M. ROWE, Nigel RUSSELL, Mohamad MOHTY, Bob LÖWENBERG, Gerard SOCIÉ, Dietger NIEDERWIESER and Gert J. GERT J. OSSENKOPPELE. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature reviews. Clinical oncology. London: Macmillan Publishers Limited, 2012, vol. 9, No 10, p. 579-590. ISSN 1759-4774. doi:10.1038/nrclinonc.2012.150. |
Other formats:
BibTeX
LaTeX
RIS
@article{991678,
author = {Cornelissen, Jan J. and Gratwohl, Alois and Schlenk, Richard F. and Sierra, Gorge and Bornhäuser, Martin and Juliusson, Gunnar and Ráčil, Zdeněk and Rowe, Jacob M. and Russell, Nigel and Mohty, Mohamad and Löwenberg, Bob and Socié, Gerard and Niederwieser, Dietger and Gert J. Ossenkoppele, Gert J.},
article_location = {London},
article_number = {10},
doi = {http://dx.doi.org/10.1038/nrclinonc.2012.150},
keywords = {allogeneic haematopoietic stem-cell transplantation; AML},
language = {eng},
issn = {1759-4774},
journal = {Nature reviews. Clinical oncology.},
title = {The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach},
volume = {9},
year = {2012}
}
TY - JOUR
ID - 991678
AU - Cornelissen, Jan J. - Gratwohl, Alois - Schlenk, Richard F. - Sierra, Gorge - Bornhäuser, Martin - Juliusson, Gunnar - Ráčil, Zdeněk - Rowe, Jacob M. - Russell, Nigel - Mohty, Mohamad - Löwenberg, Bob - Socié, Gerard - Niederwieser, Dietger - Gert J. Ossenkoppele, Gert J.
PY - 2012
TI - The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JF - Nature reviews. Clinical oncology.
VL - 9
IS - 10
SP - 579-590
EP - 579-590
PB - Macmillan Publishers Limited
SN - 17594774
KW - allogeneic haematopoietic stem-cell transplantation
KW - AML
N2 - Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic- HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual’s risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.
ER -
CORNELISSEN, Jan J., Alois GRATWOHL, Richard F. SCHLENK, Gorge SIERRA, Martin BORNHÄUSER, Gunnar JULIUSSON, Zdeněk RÁČIL, Jacob M. ROWE, Nigel RUSSELL, Mohamad MOHTY, Bob LÖWENBERG, Gerard SOCIÉ, Dietger NIEDERWIESER and Gert J. GERT J. OSSENKOPPELE. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. \textit{Nature reviews. Clinical oncology.}. London: Macmillan Publishers Limited, 2012, vol.~9, No~10, p.~579-590. ISSN~1759-4774. doi:10.1038/nrclinonc.2012.150.
|
